Because its high tumor specificity compared to other TNF family members, recombinant TRAIL, TRAIL receptor agonists and other therapeutic agents had been studied for cancer therapies by activating TRAIL pathway to induce tumor-selective apoptosis (Singh et al., 2021; von Karstedt et al., 2017; Yuan et al., 2018). The gene discussed is TNF; the disease is neoplasm.